Vasopressin as a target for antidepressant development: an assessment of the available evidence.
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the key biological abnormalities described in major depressive disorder, occurring in 30-50% of depressed subjects. Corticotropin-releasing hormone (CRH) and vasopressin (AVP) are the main regulators of this stress system, with the two neuropeptides acting synergistically in bringing about adrenocorticotropin (ACTH) release from the anterior pituitary and cortisol from the adrenal gland. Based on the demonstration of elevated cerebrospinal fluid levels of CRH in depressives, and other evidence, it has been postulated that excess CRH and the resultant increased HPA forward drive form the basis of neuroendocrine dysregulation in depression. However, there is an accumulating body of evidence to support a significant role for AVP in the regulation of pituitary-adrenal activity in health and also in depressive disorder. This review, based on a Medline search from 1980 to 2001, focuses on the functional neuroanatomy, receptor pharmacology, VP synergism with CRH, and the data from clinical and pre-clinical studies that support an important role for AVP in the pathophysiology of major depression. We suggest that future antidepressants may target the vasopressinergic system.
Scott
Lucinda V
LV
Department of Psychiatry, Cork University Hospital, Cork, Ireland. lucinda@gofree.indigo.ie
Dinan
Timothy G
TG
D000324:Adrenocorticotropic Hormone / Q000134:cerebrospinal fluid / Q000187:drug effects / Q000378:metabolism; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D003346:Corticotropin-Releasing Hormone / Q000134:cerebrospinal fluid / Q000187:drug effects / Q000378:metabolism; D003865:Major Depressive Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000503:physiopathology; D005473:Fluoxetine / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D017483:Receptors, Vasopressin / Q000187:drug effects; D014667:Vasopressins / Q000134:cerebrospinal fluid / Q000187:drug effects* / Q000378:metabolism*
D000928:Antidepressive Agents; D017483:Receptors, Vasopressin; D005473:Fluoxetine; D014667:Vasopressins; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D006854:Hydrocortisone